an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org
Author
5 papers · 2004–2024
showing 1–5 of 5 RSS
The world of pharmaceutical statistics has taken adaptive designs to its heart -at least in theory. However despite the very large number of methodological publications and presentations at conferences there are still very few examples of adaptive designs in the medical literature. In this talk I will discuss why this might be the case and will suggest areas where these approaches are likely to be of greatest value in the future.
Christos Argyropoulos, Andy P Grieve
Significance testing based on p-values has been implicated in the reproducibility crisis in scientific research, with one of the proposals being to eliminate them in favor of Bayesian analyses. Defenders of the p-values have countered that it is the improper use and errors in interpretation, rather than the p-values themselves that are to blame. Similar exchanges about the role of p-values have occurred with some regularity every 10 to 15 years since their formal introduction in statistical practice. The apparent contradiction between the repeated failures in interpretation and continuous use of p-values suggest that there is an inferential value in the computation of these values. In this work we propose to attach a radical Bayesian interpretation to the number computed and reported as a p-value for the Generalized Linear Model, which has been the workhorse of applied statistical work.…
Abstract Nobody could accuse the Royal Statistical Society's President Andy Grieve of looking for a quiet life. As well as being a consultant statistician for pharmaceuticals company Pfizer, he has for many years been heavily involved with the Society and Statisticians in the Pharmaceutical Industry. However, he claims to Helen Joyce that his early career was shaped by a fondness for “taking the easy option”.
Naoki Isogawa, Andy Grieve, Ryota Ishii +1 more
<title>Abstract</title> Under current bioequivalence guidelines in Japan, it is mandatory to establish bioequivalence using a single pivotal study. Clinical trials with limited resources usually have a pre-defined maximum permissible number of participants. In this manuscript, we considered a trial design that would allow for bioequivalence evaluation at an interim analysis in which the total number of participants takes into account the resource constraints. Then, available options at the interim analysis are group sequential designs and adaptive designs, A comparison of the performance of the two methods under a fixed maximum participant number has not been conducted thus far. So we examined which method should be used by conducting a simulation study. Since bioequivalence is expected to be achieved at the interim analysis, a study design using a Pocock-type alpha spending function is…
Abstract For the session ended June 15th, 2005, presented at the One Hundred and Seventy-first Annual General Meeting of the Royal Statistical Society, held at the premises of the Society on June 15th, 2005 President's foreword. As I come to the end of my period of office as President of the Royal Statistical Society I am constantly reminded of the enormous effort that is put into the running of the Society by many individual volunteers and the staff of Errol Street, admirably led as always by Ivor Goddard. I want to express my personal gratitude to them and to the Society's Honorary Officers. Without the efforts of these individuals the Society would not be the success that it undoubtedly is. What follows in this annual report shows a Society continuing its work in many areas of public life. As a Learned Society it continues to champion the importance of the statistical view and the…